CAR-T与阻断PD-1联合治疗在实体瘤中的研究进展  

Progress in CAR-T Cell therapy Combined with PD-1 Blockade Therapy for Solid Tumors

作　　者：郑梦 王燕[1] 缪丽燕[1,2] ZHENG Meng;WANG Yan;MIAO Liyan(Department of Clinical Pharmacology Research Laboratory,The First Affiliated Hospital of Soochow University,Suzhou 215006,China;Institute for Interdisciplinary Drug Research and Translational Sciences,Soochow University,Suzhou 215123,China)

机构地区：[1]苏州大学附属第一医院临床药理实验室,江苏苏州215006 [2]苏州大学药物研究与转化交叉研究所,江苏苏州215123

出　　处：《中国药学杂志》2024年第11期961-969,共9页Chinese Pharmaceutical Journal

基　　金：国家自然科学基金项目资助(82104318);江苏省重点研发计划(社会发展)专项资助(BE2021644)。

摘　　要：近年来,嵌合抗原受体修饰T细胞(chimeric antigen receptor-modified T cells,CAR-T)在血液系统肿瘤中的临床疗效显著,但在实体瘤的治疗中面临诸多挑战。在实体肿瘤微环境中,CAR-T细胞表面高表达的程序性细胞死亡蛋白-1(programmed cell death-1,PD-1)是限制发挥疗效的主要因素。故而,阻断PD-1可以提高CAR-T细胞的效应功能,并显著降低肿瘤负荷。本文总结了CAR-T与PD-1阻断联合治疗在实体瘤中临床前及临床中的研究现状。Recently,chimeric antigen receptor(CAR)-T cell therapy has made remarkable success in hematological malignancies but faces a series of challenges in solid tumors.One of the major problems is that CAR-T cells overexpress programmed death-1(PD-1)in tumor microenvironment.Therefore,blocking PD-1 can rescue the effector functions of CAR-T cells and reduce tumor burden significantly.Herein,it is aimed to summarize the progress in preclinical and clinical research on immunotherapy of combining CAR-T cells with PD-1 blockade for solid tumors.

关 键 词：嵌合抗原受体T细胞免疫疗法 程序性细胞死亡蛋白-1 实体瘤 免疫疗法 

分 类 号：R730.51[医药卫生—肿瘤]